TRT and high testosterone: what 'too high' actually means clinically

What did @socalurologyinstitute actually say?

Dr. Gary Bellman, a board-certified urologist, made one central argument: if your testosterone level comes back at 1,800 ng/dL while on injections, the most likely explanation is bad timing, not a bad dose. His advice was to draw blood five days after an injection, or on the morning of the day you plan to inject, so you catch a trough rather than a peak. "Don't freak out," he told viewers.

He also explained the pharmacokinetics briefly, describing testosterone as a bolus that spikes and then decays. He noted that doing labs the day after an injection puts you at the peak of that curve, which will produce a number that looks alarming but does not reflect your steady-state exposure. This is a legitimate and frequently misunderstood point, and Bellman deserves credit for addressing it directly rather than defaulting to "lower your dose."

Does the science back this up?

Yes, the core pharmacokinetic argument is well-supported. Testosterone cypionate and enanthate, the two most common injectable esters used in TRT, both exhibit a sharp post-injection peak followed by a gradual decline. The timing of blood draws relative to injection is one of the most common sources of misleading lab results in TRT management.

Ramasamy et al. (2014, Journal of Urology) documented that serum testosterone levels vary substantially depending on when in the injection cycle blood is drawn, making trough measurements the more clinically relevant benchmark for dose adjustment. Similarly, a pharmacokinetic analysis by Behre et al. (1999, Journal of Clinical Endocrinology and Metabolism) showed that testosterone enanthate produces peak serum concentrations within 24 to 48 hours of injection before declining toward baseline over seven to ten days. Bellman's framing of this as a "bolus" that "goes like this and decays" is an accurate lay description of first-order pharmacokinetics. The 1,800 ng/dL number he cites is plausible as a post-injection peak for patients on standard doses.

What did they get wrong (or right)?

Bellman got the pharmacokinetics right. Where the video gets a little loose is in implying that a peak reading of 1,800 ng/dL is automatically harmless. That framing is mostly accurate but not universally true, and the video glosses over it.

The Endocrine Society's clinical practice guidelines recommend maintaining testosterone levels within the physiologic male range, generally 400 to 700 ng/dL at trough for most patients. A sustained supraphysiologic level, even if partially an artifact of timing, can still signal that a patient's dose is on the high end of reasonable. Bellman's advice to retest at the trough is correct, but the video could have noted that if the trough reading is also elevated, a dose conversation is warranted.

He also did not mention hematocrit monitoring, which is a meaningful omission. Supraphysiologic testosterone, whether real or artifact-related, is associated with erythrocytosis. Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) identified elevated hematocrit as the most common adverse effect of TRT, occurring in roughly 15 to 44 percent of patients depending on the formulation and dose. A full fact-check of TRT management that skips hematocrit is incomplete.

What should you actually know?

If you're on injectable testosterone and your labs come back elevated, timing is the first variable to interrogate, not the dose. Bellman's advice to draw blood at the trough, either five days post-injection for weekly protocols or the morning before your next shot on more frequent schedules, is consistent with standard clinical guidance and should be the default approach.

That said, context matters. A trough reading of 1,800 ng/dL is a different clinical story than a peak reading of 1,800 ng/dL. If your trough is still supraphysiologic, a conversation with your prescriber about dose adjustment is appropriate, regardless of how the peak looks. The Endocrine Society guidelines (Bhasin et al., 2018) recommend against maintaining supraphysiologic levels as a routine practice. You should also be getting hematocrit checked, not just testosterone. That is non-negotiable on TRT and was absent from this video entirely. "Don't freak out" is good advice, but "don't skip your follow-up labs" would have been better advice to end on.